Epigenetic modifications, such as DNA methylation and histone acetylation, are well established as important
players in tumourigenesis and thereby sought after targets in therapeutic intervention. Recent years have seen an increase
in the research and clinical development of histone deacetylase (HDAC) inhibitors as anti-cancer agents, but emerging
evidence now suggests that the class of enzymes performing the reciprocal function of histone acetylation, histone acetyltransferases
(HATs), may also have pivotal roles in cancer progression. Here we discuss the role of HAT complexes in
tumourigenesis and their potential as bona fide druggable cancer targets, focusing in particular on the evolutionary conserved
Keywords: Acetylation, cancer, epigenetics, HAT inhibitors, histone acetyltransferases, MRGBP, TIP60, tumour therapy.
Rights & PermissionsPrintExport